As of December 15, 2025, Myriad Genetics Inc (MYGN) reports a Forward P/E of 826.23.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Myriad Genetics Inc's Forward P/E to Peers
To better understand Myriad Genetics Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Myriad Genetics Inc (MYGN) | 826.23 |
| Vericel Corp (VCEL) | 132.00 |
| Organogenesis Holdings Inc (ORGO) | 68.18 |
| BioCryst Pharmaceuticals Inc (BCRX) | 45.12 |
| Akebia Therapeutics Inc (AKBA) | 36.99 |
| ACADIA Pharmaceuticals Inc (ACAD) | 32.27 |
Compared to its competitors, Myriad Genetics Inc's Forward P/E is higher than all peers, reflecting higher growth expectations from investors.